- 期刊
Short Term Treatment of Duodenal Ulcer with Famotidine or Omeprazole – A Randomized, Controlled Study
以Famotidine或Omeprazole短期治療十二指腸潰瘍－隨機對照之研究
摘要
Famotidine是種第二型組織胺接受體拮抗劑，用於治療消化性潰瘍。Omeprazole是對胃壁細胞之氫鉀離子三磷酸腺核酶抑制劑。吾人報告以Famotidine或Omeprazole治療十二指腸潰瘍兩週之隨機對照研究。經電子內視鏡診斷為十二指腸潰瘍活動期之患者隨機分成兩組。一組以每日口服一次Omeprazole 20mg治療兩週。另一組以每日口服Famotidine 20mg兩次治療二週。並記錄治療過程之疼痛指數及副作用。二週後再以電子內視鏡檢查。我們的結果顯示：Omeprazole組有9位患者及Famotidine組有10位。以Omeprazole治療二週後之十二指腸潰瘍形成瘢痕率八88.9%而疼痛指數為2.6。以Famotidine治療二週後之十二指腸潰瘍瘢痕率為70% (P=0.333)而疼痛指數為4.1。Omeprazole組之疼痛指數有減少的趨勢，但兩組之十二指腸潰瘍瘢痕率及疼痛指數皆無統計上之差異。
並列摘要
Famotidine is a kind of H2-receptor antagonist which is used in the medical therapy of peptic ulcer. Omeprazole is a specific inhibitor of hydrogenpotassium ATP ase of the gastric parietal cell. We report a randomized, controlled study of short term treatment of duodenal ulcer with omeprazole or famotidine for 2 weeks. The patients with duodenal ulcer in active stage after videoendoscopic examination were randomized into two groups. One group was treated with omeprazole 20 mg once daily for 2 weeks. The other group was treated with famotidine 20 mg twice daily for 2 weeks. The index of pain and side effect was recorded during the course of treatment. Followed up videoendoscopy was performed after 2 weeks of treatment. Our results showed: omeprazole group included 9 patients (7 male, 2 female) and famotiding group included 10 patients (8 male, 2 female). The scarring rate of duodenal ulcer of the patients in omeprazole treatment was 88.9% and the mean of pain index was 2.6. The scarring rate of duodenal ulcer of the patients in famotidine treatment was 70% (P=0.333) and the mean of pain index was 4.6. The index of pain in omeprazole treatment had a declining tendency but both the scar rate and pain index had no statistically significant difference.